Cibus reports Q2 net loss of $28.5M; cash $30M; sees runway into Q4 2024

Cibus, Inc.

2024-Q2 EPS reported -$2.26 revenue$1,383,000

Net loss of $28.5M ($1.14 loss per share) vs $20.5M loss in year-ago period (not comparable due to merger).
Cash and cash equivalents $30M; expects to fund operations into Q4 2024 without additional financing.
R&D expense $13.0M (+55% YoY); SG&A $9.3M (-16% YoY).
Commercial progress: signed fourth rice HT trait customer FEDEARROZ; Wheat platform operational; Sclerotinia and NUE edits achieved in canola.
Regulatory advances in Canada, UK, EU; IP expanded across 10 trait families.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.